JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26

Benzinga Newsdesk www.benzinga.com Positive 49.7%

Neg 0% Neu 0% Pos 49.7%

JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating and announces Price Target of $26.